Article Per Year (5 Year)
p-Index From 2021 - 2026
1.978
P-Index
This Author published in this journals
All Journal Journal of Tropical Life Science : International Journal of Theoretical, Experimental, and Applied Life Sciences Jurnal Media Gizi Indonesia (MGI) The Indonesian Biomedical Journal Indonesian Journal of Cardiology Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML) Heart Science Journal JOURNAL OF COMMUNITY MEDICINE AND PUBLIC HEALTH RESEARCH Cardiovascular and Cardiometabolic Journal (CCJ) Journal of Global Pharma Technology Folia Medica Indonesiana
Budi Susetyo Pikir
Departemen Kardiologi Dan Kedokteran Vaskuler, Fakultas Kedokteran –RSUD Dr. Soetomo. Kelompok Peneliti Sel Punca – Institut Penyakit Tropik, Universitas Airlangga, Surabaya
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Environmental Science Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 14 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Cardiovascular and Cardiometabolic Journal (CCJ)

 1 
Correlation Between Bioelectrical Impedance Analysis-Measured Body Fat, Body Mass Index and Waist Circumference with Cardiovascular Risk Factors in Acute Coronary Syndrome Patients Imam Mahbub Zam Zami; Budi Susetyo Pikir
Cardiovascular and Cardiometabolic Journal Vol. 2 No. 2 (2021): Cardiovascular and Cardiometabolic Journal
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/ccj.v2i2.2021.50-58

Abstract

Estimation of fat using bioelectrical impedance analysis (BIA) is thought to be a more predictive measure of cardiovascular (CV) risk assessment than body mass index (BMI) or waist circumference (WC). Percent body fat as measured using BIA (BIA-BF%) is independently associated with future cardiovascular events namely acute myocardial infarction, ischemic heart disease. This study is conducted to determine the correlation between body fat which consists of BIA-BF%, percentage of subcutaneous adipose tissue (SAT) and visceral fat level (Visceral Adipose Tissue/VAT) measured using BIA device, BMI and WC with CV risk factors (blood pressure, blood glucose level, LDL, HDL, TG, total cholesterol, HbA1c and serum fibrinogen) in patients with acute coronary syndrome (ACS). Material and Methods : This study used a cross-sectional correlation analysis. Sample was 70 ACS patients that match with inclusion criteria. Results : We found significant correlations between BIA-BF% with diastolic blood pressure, TG, and total cholesterol (r = 0.246, r = 0.250, r = 0.348 respectively; p <0.05). There was a significant correlation between VAT with diastolic blood pressure, LDL, TG, total cholesterol, HbA1c, and fibrinogen (r = 0.299, r = 0.306, r = 0.278, r = 0.265, r = 0.292, r = 0.330 respectively, p <0.05). There was a significant correlation between the percentage SAT and HDL levels (r = 0.318; p <0.05). We found no correlation between BMI and WC with blood pressure, LDL, HDL, TG, blood glucose, HbA1c and fibrinogen levels in ACS patients. Conclusion: VAT and BIA-BF% correlate with several cardiovascular risk factors better than BMI and WC. Body fat examination using BIA may be done to manage risk factors in ACS patients.
Dapagliflozin Use in Heart Failure with Reduced Ejection Fraction Accompanied by Type 2 Diabetes Mellitus: A Systematic Review Sinta Dwi Juniar; Mochamad Yusuf Alsagaff; Budi Susetyo Pikir; Pudji Lestari
Cardiovascular and Cardiometabolic Journal Vol. 3 No. 1 (2022): Cardiovascular and Cardiometabolic Journal
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/ccj.v3i1.2022.60-74

Abstract

Abstract: Heart failure patients with reduced ejection fraction (HFrEF) respond well to pharmacological therapy and show a better prognosis. Heart failure patients with reduced ejection fraction and type 2 diabetes who were given SGLT-2 inhibitor therapy showed a strong and consistent reduction in the risk of death and hospitalization. The therapy that has recently begun to be investigated for its benefits for heart failure from the SGLT-2 inhibitor class is Dapagliflozin. The systematic review aims to analyze the effect of Dapagliflozin on the prognosis of HFrEF patients with type 2 diabetes mellitus. Material and Methods: The literature was searched from e-database PubMed, ScienceDirect, and ClinicalTrial.gov. Quality assessment was done using the Critical Appraisal Skills Program (CASP) Randomized Controlled Trial Standard Checklist. Results: A total of 22,167 patients from 4 RCTs eligible studies were included. The analysis results of all of the included studies indicate that Dapagliflozin affected the patient's prognosis. Two studies discuss mortality and hospitalization, and two studies discuss symptoms, functional status, and Quality of Life (QoL). Conclusion: Dapagliflozin can improve the prognosis of HFrEF patients with type 2 DM. The improved prognosis includes reduced mortality, reduced hospitalizations by minimizing disease worsening, reducing symptoms, improving functional status and QoL. Keyword: Cardiovascular disease, Dapagliflozin, Diabetes, Prognosis, SGLT 2 inhibitor
Co-Authors , Irma Maghfirah Andrianto Annisa Trissatharra Arnindita, Jannatin Nisa Bambang Purwanto Budi Bakti Dharmadjati Budi Utomo David Setyo Budi Dharmadjati, Budi Bakti Fita Triastuti Hendri Susilo Ilma Alfia Isaridha Imam Mahbub Zam Zami Irma Maghfirah Isaridha, Ilma Alfia Jannatin Nisa Arnindita Laurentius Andre Mochamad Yusuf Alsagaff MOCHAMMAD THAHA Mochammad Yusuf Alsagaff Mohammad Satya Bhisma Mulyanto Mulyanto Pakpahan, Cennikon Pudji Lestari Putra, Rendra Mahardhika Rendra Mahardhika Putra Rizka Amalia Romi Ermawan, Romi Setiabudi, Narendra Arya Sinta Dwi Juniar Suryantoro, Satriyo Dwi Widjiati , Widjiati Wungu, Citrawati Dyah Kencono Yudi Her Oktaviono, Yudi Her